BlinkLab to Showcase U.S. FDA Autism Trial Progress at TechKnow Invest Roadshow 2026

BlinkLab's U.S. FDA 510(k) Registrational Trial and Autism Diagnostic Platform

BlinkLab Limited is pioneering a smartphone-based diagnostic platform for autism, offering a novel early diagnosis method leveraging artificial intelligence and machine learning. Its leading product, BlinkLab Dx 1, serves as an autism diagnostic aid for clinicians by utilizing smartphones combined with AI and machine learning to capture objective, reflex-based measurements. This technology aims to facilitate earlier and more accurate autism detection, crucial for timely intervention during critical brain development stages when treatment outcomes can be significantly enhanced.

The upcoming investor presentations will highlight the company's advancements in its U.S. FDA 510(k) registrational trial—a key regulatory milestone for medical device companies seeking clearance in the U.S. The 510(k) pathway enables manufacturers to prove their product's substantial equivalence to a legally marketed predicate device, potentially expediting market authorization. For BlinkLab, this regulatory process is essential to build credibility with healthcare providers, payers, and investors as it moves to commercialize its diagnostic technology in the largest healthcare market globally.

Leadership and Scientific Expertise Driving BlinkLab's Innovation

Founded by Princeton University neuroscientists, BlinkLab benefits from strong scientific foundations in brain research and autism neurobiology. The company is guided by an experienced management team and Board specializing in digital healthcare, computer vision, and artificial intelligence—fields critical to developing and scaling smartphone-based diagnostic platforms. This blend of academic neuroscience and commercial technology leadership positions BlinkLab to bridge cutting-edge research with practical clinical applications.

Dr. Henk-Jan Boele, Managing Director and CEO, will lead the presentations at both TechKnow roadshow events, joined by Non-Executive Chairman Brian Leedman. Supporting the executive team is a Scientific Advisory Board composed of leading experts in autism and brain development, enhancing BlinkLab's credibility with clinicians, regulators, and institutional investors assessing the company’s technology and market potential.

Broadening Clinical and Research Collaborations in Autism Diagnostics

BlinkLab is actively growing its portfolio of clinical and research partnerships as part of its commercialization strategy. Such collaborations are vital in medical device and diagnostic sectors, helping validate technology efficacy, generate peer-reviewed evidence, and forge relationships with opinion leaders and early adopter institutions. Research collaborations also accelerate data collection to support regulatory filings and market access in various regions.

This expansion indicates BlinkLab’s transition from early-stage development to formal validation and clinical integration. For investors, the scope and quality of these collaborations signal market traction, clinical validity, and the company’s ability to embed itself within healthcare systems. Management will detail these developments during the TechKnow roadshow, offering investors insight into the strategic partnerships’ status and scale.

Expanding Pipeline of Neurometric Assessment Technology Applications

BlinkLab is advancing a growing pipeline of applications for its core neurometric assessment technology, extending beyond autism diagnostics. Neurometric assessment involves objective measurement of neurological and behavioral markers using technology-enabled platforms, here via smartphone systems. By broadening its application portfolio, BlinkLab explores multiple revenue streams and market opportunities, including other neurodevelopmental or neurological conditions where early, objective assessment can improve clinical outcomes.

This pipeline expansion aligns with industry trends toward digital health and biomarker-based neurological and psychiatric assessments. Objective, measurable neurological markers captured by technology can enhance diagnostic accuracy and scalability compared to subjective clinical observation. For investors, a diversified application pipeline mitigates commercial concentration risk and creates multiple revenue and value creation pathways. The investor presentations will provide further details on targeted clinical areas within the expanded pipeline.

TechKnow Invest Roadshow 2026: Platform and Investor Engagement

The TechKnow Invest Roadshow is a prominent annual event series connecting ASX-listed companies in Technology, Biotech, Medtech, and Resources Technology sectors with investors and stockbrokers. By participating in Melbourne and Sydney events, BlinkLab accesses two major Australian financial hubs, maximizing exposure to institutional investors, fund managers, retail investors, and financial advisors.

BlinkLab’s presentations are scheduled for Monday, 27 July 2026 at 12:45 pm AEST at Sofitel Melbourne on Collins, and Wednesday, 29 July 2026 at 11:45 am AEST at Swissôtel Sydney. Interested investors can register via the official TechKnow Invest Roadshow website. This platform is especially relevant for biotech and medtech companies like BlinkLab, attracting specialist investors with expertise in digital health, regulatory pathways, and healthcare innovation.

Strategic Communication of Regulatory Milestones and Market Potential

Presenting at the TechKnow Invest Roadshow underscores BlinkLab’s commitment to proactively update investors on regulatory progress and market opportunities at a critical development stage. The emphasis on the U.S. FDA 510(k) registrational trial highlights this milestone’s importance in the company’s commercialization timeline. Management aims to keep the investment community well-informed, as FDA clearance is closely watched by investors as a catalyst for market adoption and revenue growth.

By focusing on expanding collaborations and a growing application pipeline, BlinkLab positions itself as a company with multiple commercial success pathways, not reliant on a single diagnostic indication or market. This approach appeals to growth-oriented investors seeking scalable technology platforms with diversified revenue potential. Covering regulatory progress, clinical partnerships, and application expansion addresses key investor concerns about risk mitigation, market validation, and the size of the addressable market.

Autism Diagnostic Market and Early Intervention Significance

The autism diagnostic market presents a substantial healthcare opportunity fueled by rising prevalence, increased awareness, and recognition of early diagnosis benefits. Early autism identification enables access to interventions during critical neurodevelopmental periods when treatment responsiveness is highest. Current diagnostic methods often depend on subjective clinical assessments and behavioral observations, causing diagnosis delays and limiting early intervention. BlinkLab’s objective, technology-driven diagnostic platform offers clinicians quantifiable, reflex-based neurometric markers that support faster and more consistent diagnosis.

Extensive research supports the clinical value of early autism diagnosis, demonstrating improved long-term developmental outcomes with early intervention. This evidence base creates regulatory and reimbursement incentives for diagnostic tools that enable earlier identification. BlinkLab’s smartphone-based delivery model adds advantages of accessibility, scalability, and cost-effectiveness compared to traditional diagnostics. The company’s FDA 510(k) clearance pursuit reflects its prioritization of the U.S. market, considering its large pediatric population, autism prevalence, and supportive regulatory and reimbursement environment.

Princeton University Origins and Innovation Legacy

Founded by Princeton University neuroscientists, BlinkLab is grounded in peer-reviewed autism research and neurobiology. Princeton is globally recognized for neuroscience innovation related to brain development, autism etiology, and early identification markers. This academic foundation ensures BlinkLab’s diagnostic technology is based on rigorous scientific evidence rather than empirical development alone, enhancing credibility with clinicians, regulators, and investors.

Successfully translating academic research into commercial healthcare technology requires scientific validity, regulatory expertise, product development, and commercial acumen. BlinkLab’s evolution from Princeton research to an ASX-listed company with an experienced management team and scientific advisory board demonstrates effective technology transfer and commercialization. For investors, this blend of strong academic roots and commercial execution indicates a balance of scientific rigor and practical business development. The leadership’s expertise in digital healthcare, computer vision, and artificial intelligence further validates the company’s capacity to build a scalable commercial platform from its research foundations.

Core Competitive Advantages: Digital Health, AI, and Machine Learning

BlinkLab’s platform integrates three core technologies: smartphones as delivery devices, artificial intelligence, and machine learning for data analysis and interpretation. Smartphones provide a widely accessible computing platform present in billions of devices globally, lowering diagnostic access barriers compared to specialized equipment. AI and machine learning enable extraction of objective, quantifiable neurometric markers from smartphone data, reducing reliance on subjective clinical judgment. This technology stack situates BlinkLab within the digital health ecosystem and aligns with investment trends favoring software-enabled, scalable healthcare solutions.

The management team and Board’s expertise in computer vision and AI is a vital competitive edge in developing and refining diagnostic algorithms. As regulators, clinicians, and payers increasingly expect transparent and interpretable AI decision-making in digital health, BlinkLab’s technical leadership is critical for navigating regulatory requirements and achieving clinical adoption. The TechKnow roadshow presentations will likely highlight how the company’s technical capabilities distinguish its platform in the competitive digital health and diagnostics landscape.